Lee JM - Search Results

1

Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.

Robinson AN, Tebase BG, Francone SC, Huff LM, Kozlowski H, Cossari D, Lee JM, Esposito D, Robey RW, Gottesman MM. Robinson AN, et al. Among authors: lee jm. Drug Metab Dispos. 2019 Jul;47(7):715-723. doi: 10.1124/dmd.118.086181. Epub 2019 May 2. Drug Metab Dispos. 2019. PMID: 31048454 Free PMC article.

2

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer.

Nair J, Huang TT, Murai J, Haynes B, Steeg PS, Pommier Y, Lee JM. Nair J, et al. Among authors: lee jm. Oncogene. 2020 Aug;39(33):5520-5535. doi: 10.1038/s41388-020-1383-4. Epub 2020 Jul 9. Oncogene. 2020. PMID: 32647134 Free PMC article.

3

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer.

Brill E, Yokoyama T, Nair J, Yu M, Ahn YR, Lee JM. Brill E, et al. Among authors: lee jm. Oncotarget. 2017 Oct 31;8(67):111026-111040. doi: 10.18632/oncotarget.22195. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340034 Free PMC article.

4

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.

Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, Swisher EM, Harrell MI, Trepel JB, Lee MJ, Bagheri MH, Botesteanu DA, Steinberg SM, Minasian L, Ekwede I, Kohn EC. Lee JM, et al. Among authors: lee mj. Lancet Oncol. 2018 Feb;19(2):207-215. doi: 10.1016/S1470-2045(18)30009-3. Epub 2018 Jan 18. Lancet Oncol. 2018. PMID: 29361470 Free PMC article.

5

Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.

Haynes B, Murai J, Lee JM. Haynes B, et al. Among authors: lee jm. Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11. Cancer Treat Rev. 2018. PMID: 30269007 Free PMC article. Review.

6

Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.

Huang TT, Lampert EJ, Coots C, Lee JM. Huang TT, et al. Among authors: lee jm. Cancer Treat Rev. 2020 Jun;86:102021. doi: 10.1016/j.ctrv.2020.102021. Epub 2020 Apr 10. Cancer Treat Rev. 2020. PMID: 32311593 Free PMC article. Review.

7

A Phase II Single Arm Pilot Study of the CHK1 Inhibitor Prexasertib (LY2606368) in BRCA Wild-Type, Advanced Triple-Negative Breast Cancer.

Gatti-Mays ME, Karzai FH, Soltani SN, Zimmer A, Green JE, Lee MJ, Trepel JB, Yuno A, Lipkowitz S, Nair J, McCoy A, Lee JM. Gatti-Mays ME, et al. Among authors: lee mj, lee jm. Oncologist. 2020 Dec;25(12):1013-e1824. doi: 10.1634/theoncologist.2020-0491. Epub 2020 Jun 24. Oncologist. 2020. PMID: 32510664 Free PMC article. Clinical Trial.

8

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses.

Lampert EJ, Cimino-Mathews A, Lee JS, Nair J, Lee MJ, Yuno A, An D, Trepel JB, Ruppin E, Lee JM. Lampert EJ, et al. Among authors: lee js, lee mj, lee jm. J Immunother Cancer. 2020 Jul;8(2):e000516. doi: 10.1136/jitc-2019-000516. J Immunother Cancer. 2020. PMID: 32709712 Free PMC article. Clinical Trial.

9

Targeting the PI3K/mTOR Pathway Augments CHK1 Inhibitor-Induced Replication Stress and Antitumor Activity in High-Grade Serous Ovarian Cancer.

Huang TT, Brill E, Nair JR, Zhang X, Wilson KM, Chen L, Thomas CJ, Lee JM. Huang TT, et al. Among authors: lee jm. Cancer Res. 2020 Dec 1;80(23):5380-5392. doi: 10.1158/0008-5472.CAN-20-1439. Epub 2020 Sep 30. Cancer Res. 2020. PMID: 32998994 Free PMC article.

10

Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer.

Gupta N, Huang TT, Horibata S, Lee JM. Gupta N, et al. Among authors: lee jm. Pharmacol Res. 2022 Apr;178:106162. doi: 10.1016/j.phrs.2022.106162. Epub 2022 Mar 5. Pharmacol Res. 2022. PMID: 35259479 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7,066 results

Search Page